Trial · NCT00828919
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
NCT00828919, Not applicable, Completed, Pfizer; results first posted 2024-12-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials. Trials, record NCT00828919. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00828919
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
- NCT number
- NCT00828919
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 52 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Solid Tumors
- Interventions
- axitinib, crizotinib
- First posted
- 2009-01-26
- Last updated
- 2024-12-03
- Other registries' IDs
- eudract:2005-000051-15
- Results first posted
- 2024-12-03
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Day 1 up to 28 days after last dose of study drug (maximum treatment exposure was 119.56 months; maximum follow-up to approximately 120.56 months) | An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness of an AE to study drug was based on investigator's assessment. AEs included both serious and non-serious AEs. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Day 1 up to 28 days after last dose of study drug (maximum treatment exposure was 119.56 months; maximum follow-up to approximately 120.56 months) | Safety population included all participants who received at least 1 dose of Axitinib under A4061008 protocol. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Overall | TEAEs | 49 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Axitinib 2 mg | TEAEs | 7 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Axitinib 3 mg | TEAEs | 9 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Axitinib 5 mg | TEAEs | 20 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Axitinib 7 mg | TEAEs | 2 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Other | TEAEs | 11 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Overall | Serious TEAEs | 21 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Axitinib 2 mg | Serious TEAEs | 4 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Axitinib 3 mg | Serious TEAEs | 8 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs | Axitinib 5 mg | Serious TEAEs | 5 | Participants |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Axitinib 2 mg | 7 | |
| Overall Study | STARTED | Axitinib 3 mg | 9 | |
| Overall Study | STARTED | Axitinib 5 mg | 20 | |
| Overall Study | STARTED | Axitinib 7 mg | 2 | |
| Overall Study | STARTED | Other | 11 | |
| Overall Study | COMPLETED | Axitinib 2 mg | 0 | |
| Overall Study | COMPLETED | Axitinib 3 mg | 0 | |
| Overall Study | COMPLETED | Axitinib 5 mg | 0 | |
| Overall Study | COMPLETED | Axitinib 7 mg | 0 | |
| Overall Study | COMPLETED | Other | 0 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events1,512
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Overall | 3 | 49 | |
| other | Anaemia | Blood and lymphatic system disorders | Axitinib 2 mg | 0 | 7 | |
| other | Anaemia | Blood and lymphatic system disorders | Axitinib 3 mg | 0 | 9 | |
| other | Anaemia | Blood and lymphatic system disorders | Axitinib 5 mg | 3 | 20 | |
| other | Anaemia | Blood and lymphatic system disorders | Axitinib 7 mg | 0 | 2 | |
| other | Anaemia | Blood and lymphatic system disorders | Other | 0 | 11 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Overall | 4 | 49 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Axitinib 2 mg | 0 | 7 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Axitinib 3 mg | 1 | 9 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Axitinib 5 mg | 1 | 20 |
1 to 10 of 1,512Source ClinicalTrials.gov
See all 1,512 adverse eventsAdverse event totals18
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Overall | 5 | 49 |
| Total, all-cause mortality | Axitinib 2 mg | 1 | 7 |
| Total, all-cause mortality | Axitinib 3 mg | 1 | 9 |
| Total, all-cause mortality | Axitinib 5 mg | 3 | 20 |
| Total, all-cause mortality | Axitinib 7 mg | 0 | 2 |
| Total, all-cause mortality | Other | 0 | 11 |
| Total, other adverse events | Overall | 48 | 49 |
| Total, other adverse events | Axitinib 2 mg | 7 | 7 |
| Total, other adverse events | Axitinib 3 mg | 9 | 9 |
| Total, other adverse events | Axitinib 5 mg | 19 | 20 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00828919
GET https://conductscience.org/api/trials/v1/NCT00828919/results?page=2